Health workers in parts of the Democratic Republic of the Congo (DRC) have begun to receive a vaccine that many hope will provide a level of protection against the Ebola virus. The vaccine rollout started on Saturday in Bunia, the capital of Ituri province in the northeastern DRC. Ituri is the epicentre of the fastest-growing outbreak of Ebola in history. The provincial governor, Major-General Gaby Kasongo Mulumba, said health workers there “are particularly exposed and deeply involved in the response”.
The operation, backed by the World Health Organization and Doctors Without Borders, known by its French initials MSF, will also target North Kivu, where cases have been rising sharply, health authorities said. Some 50,000 health and other frontline workers will be injected with the Ervebo vaccine, which was developed for use against the more common Zaire strain. Its effectiveness against the current Ebola strain caused by the Bundibugyo virus will be monitored in 20,000 recipients for up to one year. Clinical trials are ongoing to find a licensed vaccine for the latest outbreak, which has no licensed vaccine or proven treatment. “We don’t know to what degree it might be effective against the Bundibugyo strain,” Steve Ahuka, a Congolese official who is part of the health task force against the Ebola outbreak, said.
Dr Jeannot Elua said at a health facility in Bunia the vaccine was “beneficial”. “We healthcare workers don’t really have a choice. We are going to receive it,” he told the Associated Press news agency. “Some people here had already received the previous vaccine. I received it myself, because it was mandatory.” WHO experts have said that early data on the Ervebo vaccine, notably from animal trials, suggested it could offer some protection in the current outbreak. The virus has killed at least 3,639 and infected some 7,541 people since May.
Some 1,823 people have recovered, according to the latest figures from local authorities. The WHO said in August that 70,000 doses of Ervebo were approved for use in the DRC. The vaccine is being used under a compassionate-use programme, which allows a medical product to be used in a serious disease situation even though it has not been specifically approved for that particular use. While WHO officials have cited “encouraging signs” that transmission may be slowing, MSF warned on Friday that there is no clear evidence the epidemic is coming under control.
